Article

Patent disputes ended over eye vitamins

Rochester, NY—Bausch & Lomb has resolved a pair of patent disputes involving its Ocuvite PreserVision eye vitamins.

Rochester, NY-Bausch & Lomb has resolved a pair of patent disputes involving its Ocuvite PreserVision eye vitamins.

The company, which holds worldwide patent rights to the formula developed by the Age-Related Eye Disease Study (AREDS), settled a lawsuit against Alcon Laboratories Inc. and dismissed a second against Inverness Medical Innovations Inc.

Bausch & Lomb had developed the formula for the vitamins with the National Eye Institute and supplied the tablets for the 10-year AREDS, the results of which were released in October 2001.

The companies announced March 18 that they settled the dispute by creating a cross-licensing deal in which Alcon will sell its product and grant Bausch & Lomb global rights under "one or more" Alcon patents. The terms, which were confidential, were approved by the U.S. Public Health Service, which had granted Bausch & Lomb the license.

"The product has gained significant market share and copycat products appeared thereafter," said Margaret Graham, a Bausch & Lomb spokeswoman.

Doug MacHatton, Alcon's vice president, investor relations and strategic corporate communications, was unavailable for comment.

In the Inverness dispute, Bausch & Lomb alleged in a March 8 lawsuit that Waltham, MA-based Inverness and its subsidiary IVC Industries Inc. manufacture and distribute vitamins that infringe its patent for Ocuvite PreserVision. However, 3 days later, Bausch & Lomb dismissed the lawsuit, saying the companies had provided "a written representation" that neither had infringed the Bausch & Lomb patent.

"This matter was able to be clarified quickly as a result of Inverness' thorough internal review and prompt, direct communication," Bausch & Lomb said in its press release.

"Inverness provided information to Bausch & Lomb after the lawsuit was filed and, on the basis of that information, the action was withdrawn," Graham added.

Doug Guarino, director of corporate communications for Inverness, did not return a phone call seeking comment.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.